Evaluate Vantage takes a look at the still-open deals that might come under threat from a new international clampdown.
The relatively low-key asset might at least partly be responsible for Biocryst shares more than doubling since the start of December.
The smaller company believes that its complement C3 inhibitor could make Soliris and Ultomiris redundant in PNH.
One of the biggest surprises of 2020 was how biopharma M&A emerged relatively unscathed from Covid-19.
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
The deal solves several problems for Astra, and ranks as biopharma’s fifth-biggest cross-border transaction.
As Jak inhibition takes a big knock, attention turns to other immunosuppressive mechanisms being studied in very ill Covid-19 patients.